PMID- 24932267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 7
IP  - 6
DP  - 2014 Jun
TI  - Evaluation of chromosome 17 polysomy in breast cancer by FISH analysis of whole 
      nuclei, and its clinicopathological significance.
PG  - 1954-1958
AB  - Human epidermal growth factor receptor 2 (HER2) amplification and overexpression 
      are associated with poor prognosis and resistance to cytotoxic drugs in patients 
      with breast cancer. Increases in the number of HER2 gene copies have been shown 
      to be associated with chromosome 17 polysomy. The use of whole, intact nuclei for 
      fluorescence in situ hybridization (FISH) assay improves the accuracy of the 
      results. FISH analysis of whole nuclei (WNFISH) and immunohistochemistry (IHC) 
      were used to analyze HER2 gene amplification and HER2 protein expression in 109 
      breast cancer specimens. Chromosome 17 polysomy and its correlations with HER2 
      gene amplification, HER2 protein expression and the clinicopathological outcomes 
      of the patients were also investigated. Among the 109 cases, WNFISH detected HER2 
      amplification in 30 cases, equivocal amplification in 19 cases and no 
      amplification in 60 cases. WNFISH detected chromosome 17 centromere (CEP17) 
      polysomy in 37 cases and no polysomy in 72 cases. Among the 109 cases assessed by 
      tissue microarray and IHC, 31 cases were HER2-negative, 14 cases were scored 1+, 
      23 cases were scored 2+ and 41 cases were scored 3+. The results demonstrated 
      that in the cases with chromosome 17 polysomy, the HER2 gene was amplified, HER2 
      protein expression was increased and the incidences of nuclear atypia and lymph 
      node metastases were higher compared with those in the cases without chromosome 
      17 polysomy. Chromosome 17 polysomy may correlate with increased malignant 
      potential and metastatic spread in breast cancer.
FAU - Jiang, Huiyong
AU  - Jiang H
AD  - Department of General Surgery, General Hospital of Shenyang Military Area 
      Command, Shenyang, Liaoning 110840, P.R. China.
FAU - Bai, Xiaoyan
AU  - Bai X
AD  - Division of Nephrology, Guangdong Provincial Institute of Nephrology, Nanfang 
      Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China.
FAU - Meng, Fanjun
AU  - Meng F
AD  - Department of Gastroenterology, No. 202 Hospital of People's Liberation Army, 
      Shenyang, Liaoning 110003, P.R. China.
FAU - Zhang, Cheng
AU  - Zhang C
AD  - Department of General Surgery, General Hospital of Shenyang Military Area 
      Command, Shenyang, Liaoning 110840, P.R. China.
FAU - Zhang, Xuefeng
AU  - Zhang X
AD  - Department of General Surgery, General Hospital of Shenyang Military Area 
      Command, Shenyang, Liaoning 110840, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20140328
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC4049721
OTO - NOTNLM
OT  - HER2 gene
OT  - breast cancer
OT  - fluorescence in situ hybridization
OT  - nuclei microarray
EDAT- 2014/06/17 06:00
MHDA- 2014/06/17 06:01
PMCR- 2014/03/28
CRDT- 2014/06/17 06:00
PHST- 2013/06/05 00:00 [received]
PHST- 2014/02/26 00:00 [accepted]
PHST- 2014/06/17 06:00 [entrez]
PHST- 2014/06/17 06:00 [pubmed]
PHST- 2014/06/17 06:01 [medline]
PHST- 2014/03/28 00:00 [pmc-release]
AID - ol-07-06-1954 [pii]
AID - 10.3892/ol.2014.2001 [doi]
PST - ppublish
SO  - Oncol Lett. 2014 Jun;7(6):1954-1958. doi: 10.3892/ol.2014.2001. Epub 2014 Mar 28.